TD Asset Management Inc Has $46.72 Million Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• TD Asset Management Inc reduced its holdings in Amphastar Pharmaceuticals by 8.0%, now owning 2,034,930 shares valued at approximately $46.72 million.
• Several analysts have adjusted their ratings on Amphastar Pharmaceuticals, with a consensus target price of $31.60 and mixed ratings, including two "Buy" and four "Hold" ratings.
• The stock opened at $23.22, with a market capitalization of $1.08 billion, and has a P/E ratio of 8.70.

TD Asset Management Inc lessened its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 8.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,034,930 shares of the company's stock after selling 177,212 shares during the quarter. TD Asset Management Inc owned 4.32% of Amphastar Pharmaceuticals worth $46,722,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. raised its stake in shares of Amphastar Pharmaceuticals by 14.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company's stock valued at $400,000 after purchasing an additional 1,694 shares during the period. Picton Mahoney Asset Management raised its stake in shares of Amphastar Pharmaceuticals by 6,600.0% in the 1st quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company's stock valued at $46,000 after purchasing an additional 1,584 shares during the period. Graham Capital Management L.P. acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter valued at about $766,000. Allspring Global Investments Holdings LLC raised its stake in shares of Amphastar Pharmaceuticals by 9.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,326 shares of the company's stock valued at $434,000 after purchasing an additional 1,262 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter valued at about $532,000. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Up 0.3%

Amphastar Pharmaceuticals stock opened at $23.22 on Friday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $20.39 and a 52 week high of $53.96. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29. The stock has a market capitalization of $1.08 billion, a P/E ratio of 8.70 and a beta of 0.75. The stock has a 50-day simple moving average of $27.86 and a 200 day simple moving average of $25.30.

Analyst Upgrades and Downgrades

Several analysts have issued reports on AMPH shares. Bank of America lifted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. Weiss Ratings reissued a "hold (c-)" rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, October 8th. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research report on Friday, August 8th. Finally, Needham & Company LLC raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 target price on the stock in a research report on Tuesday, August 12th. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.